Fadrozole

Fadrozole
Clinical data
Routes of
administration
Oral
ATC code none
Legal status
Legal status
  • ℞ (Prescription only)
Identifiers
CAS Number 102676-31-3 YesY
PubChem (CID) 59693
ChemSpider 53850 N
UNII H3988M64PU N
KEGG D02451 YesY
ChEMBL CHEMBL9298 N
ECHA InfoCard 100.159.562
Chemical and physical data
Formula C14H13N3
Molar mass 223.27 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Fadrozole (INN, marketed as Afema by Novartis) is a selective[1] aromatase inhibitor[2] that has been introduced in Japan for the treatment of breast cancer.

References

  1. Browne LJ, Gude C, Rodriguez H, Steele RE, Bhatnager A (February 1991). "Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease". J. Med. Chem. 34 (2): 725–36. doi:10.1021/jm00106a038. PMID 1825337.
  2. Raats JI, Falkson G, Falkson HC (January 1992). "A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer". J. Clin. Oncol. 10 (1): 111–6. PMID 1530798.


This article is issued from Wikipedia - version of the 9/16/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.